SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (496)10/16/1998 5:19:00 PM
From: Jean-Robert Grenier  Respond to of 783
 
Hi Richard !

Thank you for your analysis. I like te way you think. I would add to that : more the interest rate will go down more the market will accept higher P/E. If we take into consideration the perspective of a recession in 1999, Company's that will generate increase revenues will catched the investors attention. I hope that this will be the case of BCHE.

Au revoir
Jean-Robert



To: Richard Haugland who wrote (496)10/17/1998 8:22:00 PM
From: Steve Lokness  Read Replies (1) | Respond to of 783
 
Richard;
Assuming your estimates for lamivudine are correct, would this not offer an interesting market to a company able to measure viral load? (see VGINF) Do you have an opinion of the hybrid capture method as compared to others?

Thanks;

steve


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News